Janssen Biotech, Inc. announced that the FDA has approved Tremfya (guselkumab) for the treatment of adults living with moderate to...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced comprehensive efficacy and safety data from the DISCOVER–2 trial of Tremfya (guselkumab) were published in Arthritis & Rheumatology, representing the final results of the first two-year clinical trial investigating a selective interleukin (IL)-23 inhibitor therapy in active psoriatic arthritis (PsA)
Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada has approved Tremfya (guselkumab injection) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the ECLIPSE study demonstrating that Tremfya (guselkumab) was superior...
If approved, guselkumab will be the first selective IL-23 p19 subunit inhibitor for people in the European Union with active psoriatic arthritis.
The UK NICE has recommended the use of Tremfya (guselkumab), from Janssen, as a cost-effective treatment for plaque psoriasis for...
Plaque psoriasis Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Psoriatic arthritis Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy (see section 5.1).
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Tremfya One-Press
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a supplemental Biologics License Application (sBLA) to the...